Funding – Page 2

Berkeley startup raises $106.5M for all‑RNA ‘jumping gene’ therapies

4 weeks ago talkbio0Tagged Berkeley, Cells, Funding, gene therapy, jumping gene, M financing, programmable RNA medicines, Radar Therapeutics, RNA gene, Series A

Radar Therapeutics; Berkeley startup; $106.5M financing; Series A; jumping gene; RNA gene insertion; programmable RNA medicines; cell and gene therapy; biotech funding

Pilatus Raises $14M for First-in-Human Study of Anti-CD36 mAb

4 weeks ago talkbio0Tagged Anti-CD36 mAb, First-in-Human Study, Funding, Pilatus

Pilatus; funding; anti-CD36 mAb; first-in-human study; biotech

Scaling for a New Era: The Rise of Radiopharma

4 weeks ago talkbio0Tagged Clinical Trials, CROs, Diagnostics, Funding, Lutetium-177, M&A, Neoplasms, Pet Animal, precision oncology, radioligand therapy, Radiopharmaceuticals, radiotheranostics, Research Infrastructure, supply chain, targeted alpha therapy

radiopharmaceuticals; radioligand therapy; oncology; precision oncology; targeted alpha therapy; Lutetium-177; Actinium-225; clinical trials; radiotheranostics; M&A; biotech funding; supply chain; infrastructure; CROs; companion diagnostics

Profluent Raises $106M to Accelerate Frontier AI Models for Programmable Biology, Backed by Jeff Bezos

2 months ago talkbio0Tagged AI biotech, Altimeter Capital, Bezos Expeditions, Biological Factors, Clustered Regularly Interspaced Short Palindromic Repeats, Drug Development, Funding, Jeff, Profluent, Programmable Biology, Protein Atlas, protein design, Synthetic Biology

Profluent; AI biotech; protein design; programmable biology; Jeff Bezos; Altimeter Capital; $106M funding; Bezos Expeditions; CRISPR; biologics; Protein Atlas; synthetic biology; drug development

Arena BioWorks Shuts Down After Investors Withdraw Support for Bold Biotech Model

2 months ago talkbio0Tagged Arena BioWorks, Biomedical Research, concerns, Funding, funding environment, Industry, investor, layoffs, Policy, shutdown, Uncertainty

Arena BioWorks; biotech shutdown; policy uncertainty; funding environment; biomedical research; $500 million funding; layoffs; biotech industry; investor concerns

Jennifer Doudna’s Azalea Therapeutics Launches with $82M to Advance In Vivo CAR-T Using Novel CRISPR Delivery Technology

2 months ago talkbio0Tagged Autoimmune Diseases, Azalea Therapeutics, B-cell malignancies, Cancer Therapeutic Procedure, CAR-T, Clustered Regularly Interspaced Short Palindromic Repeats, EDV technology, Funding, Gene Modification, in vivo, Jennifer Doudna, Series A

Jennifer Doudna; Azalea Therapeutics; CRISPR; in vivo CAR-T; gene editing; EDV technology; cancer therapy; autoimmune disease; Series A funding; B-cell malignancies

Zag Bio Launches with $80M to Teach the Immune System to Make Better Tregs

2 months ago talkbio0Tagged AbbVie, Autoimmune Diseases, Diabetes Mellitus, Insulin-Dependent, Funding, Immune Tolerance, Regeneron, Regulatory T-Lymphocytes, sanofi, Series A, thymus-targeted therapy, Tregs, Zag Bio

Zag Bio; Tregs; regulatory T cells; autoimmune diseases; thymus-targeted therapy; Series A funding; immune tolerance; Type 1 diabetes; AbbVie; Regeneron; Sanofi

Apptronik Raises $350 Million Series A to Scale AI Humanoid Robot Production

3 months ago talkbio0Tagged AI humanoid robots, Apollo robot, Apptronik, Funding, Robotics, Series A, venture capital

Apptronik; Series A funding; AI humanoid robots; Apollo robot; venture capital; robotics

Boehringer Ingelheim Strikes Nearly $1B ADC Deal with AimedBio; EyePoint Pharmaceuticals Announces $150M Stock Sale

3 months ago talkbio0Tagged AimedBio, Antibody-Drug Conjugates, Biopharma, Boehringer Ingelheim, Cancer Therapeutic Procedure, EyePoint, Funding, Licensing, stock sale, therapeutic autologous dendritic cells

Boehringer Ingelheim; AimedBio; antibody-drug conjugate; ADC; cancer therapy; biotech licensing deal; EyePoint Pharmaceuticals; stock sale; biopharma funding

Are the Good Times in Biotech Back? – Insights from Post-Hoc Live’s 2025 Industry Sentiment

3 months ago talkbio0Tagged Aggressive Periodontitis, delays, executive survey, Funding, Industry, M&A, Post-Hoc Live, public biotech, Sentiment, United States Food and Drug Administration

biotech sentiment; Post-Hoc Live; 2025 industry outlook; biotech M&A; FDA delays; executive survey; public biotech companies; JP Morgan effect; biotech funding